Zobrazeno 1 - 10
of 190
pro vyhledávání: '"M Chakinala"'
Autor:
Hunter Gillies, Murali M. Chakinala, Benjamin T. Dake, Jeremy P. Feldman, Marius M. Hoeper, Marc Humbert, Zhi‐Cheng Jing, Jonathan Langley, Vallerie V. McLaughlin, Ralph W. Niven, Stephan Rosenkranz, Xiaosha Zhang, Nicholas S. Hill
Publikováno v:
Pulmonary Circulation, Vol 14, Iss 1, Pp n/a-n/a (2024)
Abstract AV‐101 (imatinib) powder for inhalation, an investigational dry powder inhaled formulation of imatinib designed to target the underlying pathobiology of pulmonary arterial hypertension, was generally well tolerated in healthy adults in a p
Externí odkaz:
https://doaj.org/article/6cca6181d66a4a5aadc281acfa6b68ed
Autor:
Harrison W. Farber, Murali M. Chakinala, Michelle Cho, Robert P. Frantz, Andrew Frick, Lisa Lancaster, Scott Milligan, Ronald Oudiz, Sumeet Panjabi, Yuen Tsang, Steven D. Nathan
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 3, Pp n/a-n/a (2023)
Abstract Pulmonary arterial hypertension (PAH) is a rare, life‐limiting disease. PAH registries provide real‐world data that complement clinical trial data and inform treatment decisions. The TRIO comprehensive, integrated patient data repository
Externí odkaz:
https://doaj.org/article/9450ffb2f427410cb5f40faf8efb0c23
Autor:
Megan Mayer, David B. Badesch, Kelly H. Nielsen, Steven Kawut, Todd Bull, John J. Ryan, Jeffrey Sager, Sula Mazimba, Anna Hemnes, James Klinger, James Runo, John W. McConnell, Teresa De Marco, Murali M. Chakinala, Delphine Yung, Jean Elwing, Adolfo Kaplan, Rahul Argula, Raymond Pomponio, Ryan Peterson, Peter Hountras
Publikováno v:
Pulmonary Circulation, Vol 13, Iss 2, Pp n/a-n/a (2023)
Abstract To better understand the impact of the COVID‐19 pandemic on the care of patients with pulmonary hypertension, we conducted a retrospective cohort study evaluating health insurance status, healthcare access, disease severity, and patient re
Externí odkaz:
https://doaj.org/article/2e5ecf9698454f89883f1139645ab4b7
Autor:
Hunter Gillies, Ralph Niven, Benjamin T. Dake, Murali M. Chakinala, Jeremy P. Feldman, Nicholas S. Hill, Marius M. Hoeper, Marc Humbert, Vallerie V. McLaughlin, Martin Kankam
Publikováno v:
ERJ Open Research, Vol 9, Iss 2 (2023)
Background Oral imatinib has been shown to be effective, but poorly tolerated, in patients with advanced pulmonary arterial hypertension (PAH). To maintain efficacy while improving tolerability, AV-101, a dry powder inhaled formulation of imatinib, w
Externí odkaz:
https://doaj.org/article/6e8ff00f40604cb1bb338a1660e59c87
Autor:
Kevin Y. Chang, Sue Duval, David B. Badesch, Todd M. Bull, Murali M. Chakinala, Teresa De Marco, Robert P. Frantz, Anna Hemnes, Stephen C. Mathai, Erika Berman Rosenzweig, John J. Ryan, Thenappan Thenappan
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 11, Iss 9 (2022)
Background Current mortality data for pulmonary arterial hypertension (PAH) in the United States are based on registries that enrolled patients prior to 2010. We sought to determine mortality in PAH in the modern era using the PHAR (Pulmonary Hyperte
Externí odkaz:
https://doaj.org/article/6095b01f3f084472a0180b96e7214fe7
Autor:
Franck F. Rahaghi, Vijay P. Balasubramanian, Robert C. Bourge, Charles D. Burger, Murali M. Chakinala, Michael S. Eggert, Jean M. Elwing, Jeremy Feldman, Christopher King, James R. Klinger, Stephen C. Mathai, John Wesley McConnell, Harold I. Palevsky, Ricardo Restrepo‐Jaramillo, Zeenat Safdar, Jeffrey S. Sager, Namita Sood, Roxana Sulica, R. James White, Nicholas S. Hill
Publikováno v:
Pulmonary Circulation, Vol 12, Iss 2, Pp n/a-n/a (2022)
Abstract Dual combination therapy with a phosphodiesterase‐5 inhibitor (PDE5i) and endothelin receptor antagonist is recommended for most patients with intermediate‐risk pulmonary arterial hypertension (PAH). The RESPITE and REPLACE studies sugge
Externí odkaz:
https://doaj.org/article/9f5b66c79cd442eda20ab75c66cf4ff1
Autor:
R. James White, Anton Vonk-Noordegraaf, Stephan Rosenkranz, Ronald J. Oudiz, Vallerie V. McLaughlin, Marius M. Hoeper, Ekkehard Grünig, Hossein-Ardeschir Ghofrani, Murali M. Chakinala, Joan A. Barberà, Christiana Blair, Jonathan Langley, Adaani E. Frost
Publikováno v:
Respiratory Research, Vol 20, Iss 1, Pp 1-10 (2019)
Abstract Background Initial combination therapy with ambrisentan and tadalafil reduced the risk of clinical failure events for treatment-naïve participants with pulmonary arterial hypertension (PAH) as compared to monotherapy. Previous studies in PA
Externí odkaz:
https://doaj.org/article/f44fd922b4584cd3b84761a83b713dd5
Publikováno v:
Pulmonary Circulation, Vol 10 (2020)
Externí odkaz:
https://doaj.org/article/1ed74d70ffb0422390c58ebf4a3b10b4
Autor:
HUNTER GILLIES, MURALI M CHAKINALA, BEN DAKE, JEREMY P FELDMAN, MARIUS M HOEPER, MARC HUMBERT, ZHI-CHENG JING, JONATHAN LANGLEY, VALLERIE MCLAUGHLIN, RALPH NIVEN, STEPHAN H. ROSENKRANZ, XIAOSHA ZHANG, NICHOLAS S HILL
Publikováno v:
Chest. 162:A2325-A2329
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::78053ee4d208eac727bbd6c2fd6fdf95
https://doi.org/10.1016/j.chest.2022.08.1923
https://doi.org/10.1016/j.chest.2022.08.1923
Autor:
Mardi Gomberg-Maitland, Robert C. Bourge, Shelley M. Shapiro, James H. Tarver, Dianne L. Zwicke, Jeremy P. Feldman, Murali M. Chakinala, Robert P. Frantz, Fernando Torres, Remzi Bag, Jeffrey A. Murphy, Amy A. Lautenbach, Marty Morris, Leigh Peterson, Aaron B. Waxman
Publikováno v:
Pulmonary Circulation, Vol 9 (2019)
Background The DelIVery for Pulmonary Arterial Hypertension clinical trial was a multi-center, prospective, single arm, Investigational Device Exemption study utilizing a fully implantable, programmable intravascular delivery system consisting of a p
Externí odkaz:
https://doaj.org/article/a1433a8c30ea4b7b98bec409679d6037